Literature DB >> 20812013

[cFLIP diminishes CD95-induced apoptosis of CD30-stimulated cutaneous anaplastic large T cell lymphoma (cALCL) cells].

B Hirsch1, F K Braun, N Al-Yacoub, C Assaf, M E Kadin, W Sterry, J Eberle, H Dürkop.   

Abstract

Stimulation of the TNF receptors CD30 and CD95 exerts opposite effects. Crosstalk of both receptors is unknown. We aimed to reveal regulatory mechanisms of CD30-induced effects on CD95 signaling of cALCL cell lines. "CD30/CD95 crosstalk analysis" was performed in cALCL cell lines by comparison of CD30 or CD95 stimulation and CD30/CD95 costimulation. Receptor expression and induction of apoptosis was investigated by flow cytometry. mRNA expression of CD30-inducible genes (cFLIP, TRAF1, cIAP2, and A20) was compared by semiquantitative reverse transcription (RT-RQ-) PCR in stimulated and unstimulated cells. Protein expression of IκBα, p100/p52, caspase-8, caspase-3, and cFLIP was analyzed by immunoblotting. A lentiviral-based shRNA-mediated approach was used to inhibit cFLIP expression. CD30/CD95 crosstalk experiments revealed that CD30 ligation leads to NFκB-mediated cFLIP upregulation in cALCL cells, which in turn enhanced resistance to CD95-mediated apoptosis. This effect is based on the CD30-induced upregulation of cFLIP. Knockdown of cFLIP restores sensitivity to CD95-mediated apoptosis. We conclude that the anti-apoptotic function of CD30 antibodies should be kept in mind if CD30 antibody-based therapeutic concepts for ALCL lymphoma are considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812013     DOI: 10.1007/s00292-010-1372-4

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  15 in total

1.  The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex.

Authors:  Olivier Micheau; Margot Thome; Pascal Schneider; Nils Holler; Jürg Tschopp; Donald W Nicholson; Christophe Briand; Markus G Grütter
Journal:  J Biol Chem       Date:  2002-09-04       Impact factor: 5.157

Review 2.  Anti-CD30 Antibodies for Hodgkin lymphoma.

Authors:  Kelley V Foyil; Nancy L Bartlett
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

3.  CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299.

Authors:  G Hübinger; E Müller; I Scheffrahn; C Schneider; E Hildt; B B Singer; I Sigg; J Graf; L Bergmann
Journal:  Oncogene       Date:  2001-02-01       Impact factor: 9.867

4.  The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.

Authors:  Boris Böll; Hinrich Hansen; Friederike Heuck; Katrin Reiners; Peter Borchmann; Achim Rothe; Andreas Engert; Elke Pogge von Strandmann
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

5.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.

Authors:  Douglas A Rubinson; Christopher P Dillon; Adam V Kwiatkowski; Claudia Sievers; Lili Yang; Johnny Kopinja; Dina L Rooney; Mingdi Zhang; Melanie M Ihrig; Michael T McManus; Frank B Gertler; Martin L Scott; Luk Van Parijs
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

Review 6.  Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer.

Authors:  Marina Bagnoli; Silvana Canevari; Delia Mezzanzanica
Journal:  Int J Biochem Cell Biol       Date:  2009-11-22       Impact factor: 5.085

Review 7.  Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.

Authors:  Min Li-Weber; Peter H Krammer
Journal:  Semin Immunol       Date:  2003-06       Impact factor: 11.130

8.  A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.

Authors:  Nancy L Bartlett; Anas Younes; Matthew H Carabasi; Andres Forero; Joseph D Rosenblatt; John P Leonard; Steven H Bernstein; R Gregory Bociek; Jennie M Lorenz; Bruce W Hart; Jeremy Barton
Journal:  Blood       Date:  2007-12-13       Impact factor: 22.113

Review 9.  Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo.

Authors:  B Hirsch; J Brauer; M Fischdick; C Loddenkemper; S Bulfone-Paus; H Stein; H Dürkop
Journal:  Curr Drug Targets       Date:  2009-02       Impact factor: 3.465

10.  c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.

Authors:  Stephan Mathas; Andreas Lietz; Ioannis Anagnostopoulos; Franziska Hummel; Burkhard Wiesner; Martin Janz; Franziska Jundt; Burkhard Hirsch; Korinna Jöhrens-Leder; Hans-Peter Vornlocher; Kurt Bommert; Harald Stein; Bernd Dörken
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.